Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Open accessThe DOI matches its Crossref record; 273 of the 276 references it cites were found in a registry or an index.
Abstract
We describe a recently recognized disease entity, limbic-predominant age-related TDP-43 encephalopathy (LATE). LATE neuropathological change (LATE-NC) is defined by a stereotypical TDP-43 proteinopathy in older adults, with or without coexisting hippocampal sclerosis pathology. LATE-NC is a common TDP-43 proteinopathy, associated with an amnestic dementia syndrome that mimicked Alzheimer's-type dementia in retrospective autopsy studies. LATE is distinguished from frontotemporal lobar degeneration with TDP-43 pathology based on its epidemiology (LATE generally affects older subjects), and relatively restricted neuroanatomical distribution of TDP-43 proteinopathy. In community-based autopsy cohorts, ∼25% of brains had sufficient burden of LATE-NC to be associated with discernible cognitive impairment. Many subjects with LATE-NC have comorbid brain pathologies, often including amyloid-β plaques and tauopathy. Given that the 'oldest-old' are at greatest risk for LATE-NC, and subjects of advanced age constitute a rapidly growing demographic group in many countries, LATE has an expanding but under-recognized impact on public health. For these reasons, a working group was convened to develop diagnostic criteria for LATE, aiming both to stimulate research and to promote awareness of this pathway to dementia. We report consensus-based recommendations including guidelines for diagnosis and staging of LATE-NC. For routine autopsy workup of LATE-NC, an anatomically-based preliminary staging scheme is proposed with TDP-43 immunohistochemistry on tissue from three brain areas, reflecting a hierarchical pattern of brain involvement: amygdala, hippocampus, and middle frontal gyrus. LATE-NC appears to affect the medial temporal lobe structures preferentially, but other areas also are impacted. Neuroimaging studies demonstrated that subjects with LATE-NC also had atrophy in the medial temporal lobes, frontal cortex, and other brain regions. Genetic studies have thus far indicated five genes with risk alleles for LATE-NC: GRN, TMEM106B, ABCC9, KCNMB2, and APOE. The discovery of these genetic risk variants indicate that LATE shares pathogenetic mechanisms with both frontotemporal lobar degeneration and Alzheimer's disease, but also suggests disease-specific underlying mechanisms. Large gaps remain in our understanding of LATE. For advances in prevention, diagnosis, and treatment, there is an urgent need for research focused on LATE, including in vitro and animal models. An obstacle to clinical progress is lack of diagnostic tools, such as biofluid or neuroimaging biomarkers, for ante-mortem detection of LATE. Development of a disease biomarker would augment observational studies seeking to further define the risk factors, natural history, and clinical features of LATE, as well as eventual subject recruitment for targeted therapies in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Statistical analyses on data related to LATE from the Rush University community-based autopsy cohort depicting the results of pathway analyses. Data were analysed from research volunteers (total n = 1309) in two clinical‐pathological studies of ageing from Rush University as described previously (Power et al., 2018). In this sample, the mean age of death was 89.7 years [standard deviation (SD) 6.5 years, range 65–108 years]. These analyses incorporated age, density of amyloid-β neuritic amyloid plaques (to factor in ADNC), TDP-43 proteinopathy, hippocampal sclerosis pathology, and the endpoint of Alzheimer’s-type clinical dementia. The components of the pathway analyses most strongly associated with LATE-NC are shown in red. The numbers are path coefficients with standard error in parentheses (shown in purple). These numbers help to quantify the effects of individual pathways. For instance, the data are compatible with there being two pathways from TDP-43 proteinopathy to dementia, one direct pathway (TDP-43 proteinopathy→dementia) and the other indirect pathway that includes hippocampal sclerosis pathology (TDP-43 proteinopathy→hippocampal sclerosis→dementia): in the statistical model, the TDP-43 proteinopathy is independently associated with both hippocampal sclerosis pathology and clinical dementia status. Further, the data indicate that a subset of TDP-43 proteinopathy is ‘downstream’ of ADNC-type neuritic amyloid plaque pathology. In a practical sense, this means that brains with more neuritic amyloid plaques are more likely to have TDP-43 proteinopathy, with all other known factors being the same. Aβ = amyloid-β.](https://figures.cochat.ai/paper-figures/9bc83b3adf7f42d5a250b59d9652e7a1/limbic-predominant-age-related-tdp-43-encephalopathy-late-consensus-working-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A consensus group, for example, has described hippocampal sclerosis associated with TDP-43 proteinopathy, as limbic-predominant age-related TDP-43 encephalopathy (LATE) dementia, usually found in people older than 80 years, progressing more slowly than Alzheimer's disease, detectable at post-mortem, often mimicking or comorbid with Alzheimer's disease.3”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“50–60% of Alzheimer’s-type dementia (dementia defined clinically as Alzheimer’s disease) is estimated to be attributable to these copathologies.40,42–45”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [45]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“LATE is a recently described entity which affects older people and presents with an amnestic picture resembling Alzheimer's disease 178 .”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [178]
The cited source says what the claim attributes to it.
In the citing paper
“Limbic-predominant age-related TDP43 encephalopathy (LATE), defined approximately 3 years ago, is a condition in which typical TDP43 protein inclusions are present with or without coexisting hippocampal sclerosis.29”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“The predominant neuropathological change in LATE is TDP-43 proteinopathy, which is associated with a clinical presentation of amnestic dementia that can mimic Alzheimer's dementia.”
From Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy (2020) · cites this paper as [20]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
Self-citationBlessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117 · cited 1×
“LATE-NC is mostly seen in the oldest-old, whereas in early clinical-pathological correlation studies of dementia (Roth et al., 1966; Blessed et al., 1968), the research subjects had died in their early 70s.”
BackgroundAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“This stratification will enable enrichment for subjects on the ADNC continuum (Sevigny et al., 2016) while excluding subjects likely to have high risk for LATE-NC (Botha et al., 2018).”
BackgroundMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
Self-citationStages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“seen at autopsy with every year of advanced old age (Braak et al., 2011; Nelson et al., 2011a, 2013; Brenowitz et al., 2014; Neltner et al., 2016).”
BackgroundPorta, M. (2026) · doi:10.1093/acref/9780197663639.001.0001 · Cited by 2,175
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Self-citation
Research works printed but not linked: 3
- Kuslansky G, Verghese J, Dickson D, Katz M, Busche H, Lipton RB Hippocampal sclerosis: cognitive consequences and contribution to dementia. Neurology 2004; 62: A128– 9.
- Porta M. Dictionary of Epidemiology. 6th edn. New York: Oxford University Press; 2014.
- Thom M, Sisodiya S Epilepsy. In: Love S, Perry A, Ironside JW, Budka H, editors. Greenfield’s Neuropathology. New York: CRC Press; 2015 p. 683– 739.
Cited by
Items 101–200 of 1,004
Dysregulation of Systemic Immunity in Aging and Dementia
Lutshumba, J., Nikolajczyk, B. S., & Bachstetter, A. D. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.652111 · Cited by 101
Neuropathology of Dementia Disorders
Schneider, J. A. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001137 · Cited by 106
Self-citationLoss of TDP‐43 oligomerization or RNA binding elicits distinct aggregation patterns
Pérez‐Berlanga, M., Wiersma, V. I., Zbinden, A., Vos, L. D., Wagner, U., Foglieni, C., Mallona, I., Betz, K. M., Cléry, A., Weber, J., et al. (2023) · The EMBO Journal · doi:10.15252/embj.2022111719 · Cited by 106
Devanand, D. P., Lee, S., Huey, E. D., & Goldberg, T. E. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.4363 · Cited by 105
Calderón-Garcidueñas, L., González-Maciel, A., Reynoso-Robles, R., Hammond, J., Kulesza, R., Lachmann, I., Torres-Jardón, R., Mukherjee, P. S., & Maher, B. A. (2020) · Environmental Research · doi:10.1016/j.envres.2020.110139 · Cited by 96
Limbic-predominant age-related TDP-43 encephalopathy, ADNC pathology, and cognitive decline in aging
Kapasi, A., Yu, L., Boyle, P. A., Barnes, L. L., Bennett, D. A., & Schneider, J. A. (2020) · Neurology · doi:10.1212/wnl.0000000000010454 · Cited by 105
Self-citationRegulation of TDP-43 phosphorylation in aging and disease
Eck, R. J., Kraemer, B. C., & Liachko, N. F. (2021) · GeroScience · doi:10.1007/s11357-021-00383-5 · Cited by 103
Fluid biomarkers for amyotrophic lateral sclerosis: a review
Irwin, K. E., Sheth, U., Wong, P. C., & Gendron, T. F. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00685-6 · Cited by 104
Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance
Geula, C., Dunlop, S. R., Ayala, I., Kawles, A. S., Flanagan, M. E., Gefen, T., & Mesulam, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15471 · Cited by 102
“FTLD can also cause the amnestic phenotype of DAT (Nelson et al., 2019).”
BackgroundInfluentialSelf-citationIs tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity
Weigand, A. J., Bangen, K. J., Thomas, K. R., Delano-Wood, L., Gilbert, P. E., Brickman, A. M., Bondi, M. W., & Initiative, A. D. N. (2020) · Brain Communications · doi:10.1093/braincomms/fcz046 · Cited by 86
Thal, D. R., & Tomé, S. O. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.10.006 · Cited by 84
Seeding the aggregation of TDP-43 requires post-fibrillization proteolytic cleavage
Kumar, S. T., Nazarov, S., Porta, S., Maharjan, N., Cendrowska, U., Kabani, M., Finamore, F., Xu, Y., Lee, V. M. ‐., & Lashuel, H. A. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01341-4 · Cited by 98
Noh, M., Kwon, H. S., Kwon, M., Nahm, M., Jin, H. K., Bae, J., & Kim, S. H. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00867-4 · Cited by 97
Shih, Y.-H., Tu, L.-H., Chang, T.-Y., Ganesan, K., Chang, W.-W., Chang, P.-S., Fang, Y.-S., Lin, Y.-T., Jin, L.-W., & Chen, Y.-R. (2020) · Nature Communications · doi:10.1038/s41467-020-19786-7 · Cited by 91
Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice
Feng, T., Mai, S., Roscoe, J. M., Sheng, R. R., Ullah, M., Zhang, J., Katz, I. I., Yu, H., Xiong, W., & Hu, F. (2020) · The EMBO Reports · doi:10.15252/embr.202050219 · Cited by 94
“Secondly, a recent study identified GRN and TMEM106B as two of the five risk factors for a recently recognized disease entity, limbic-predominant age-related TDP-43 encephalopathy (LATE) (Nelson et al , 2019).”
Alzheimer’s Disease Neuropathological Comorbidities are Common in the Younger-Old
Beach, T. G., & Malek-Ahmadi, M. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-201213 · Cited by 84
Mehta, R. I., & Schneider, J. A. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000912 · Cited by 84
Self-citationYu, L., Boyle, P. A., Janelidze, S., Petyuk, V., Wang, T., Bennett, D. A., Hansson, O., & Schneider, J. A. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02570-4 · Cited by 94
Self-citationTherriault, J., Pascoal, T. A., Benedet, A. L., Tissot, C., Savard, M., Chamoun, M., Lussier, F., Kang, M. S., Berzgin, G., Wang, T., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011416 · Cited by 91
Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer’s disease
Strom, A., Iaccarino, L., Edwards, L., Lesman-Segev, O. H., Soleimani-Meigooni, D. N., Pham, J., Baker, S. L., Landau, S. M., Jagust, W. J., Miller, B. L., et al. (2022) · Brain · doi:10.1093/brain/awab294 · Cited by 91
“These include MTL TDP-43 pathology, 96–98 an entity also known as limbic-predominant age-related TDP-43 encephalopathy 99 and often associated with hippocampal sclerosis, and argyrophilic grain disease.”
Mapping of SARS-CoV-2 Brain Invasion and Histopathology in COVID-19 DiseasePreprint
Serrano, G. E., Walkera, J., Arce, R., Glass, M. J., Vargas, D., Sue, L. I., Intorcia, A. J., Nelson, C. M., Oliver, J., Papa, J. D., et al. (2021) · medRxiv · doi:10.1101/2021.02.15.21251511 · Cited by 91
Self-citationNeuropathological assessment of the Alzheimer spectrum
Jellinger, K. A. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02232-9 · Cited by 89
Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies
Young, A. L., Vogel, J. W., Robinson, J. L., McMillan, C. T., Ossenkoppele, R., Wolk, D. A., Irwin, D. J., Elman, L. B., Grossman, M., Lee, V. M. ‐., et al. (2023) · Brain · doi:10.1093/brain/awad145 · Cited by 90
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 90
Self-citationTDP-43 pathology: From noxious assembly to therapeutic removal
Keating, S. S., Gil, R. S., Swanson, M. E. V., Scotter, E. L., & Walker, A. K. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102229 · Cited by 89
Cho, H., Mundada, N. S., Apostolova, L. G., Carrillo, M. C., Shankar, R. P., Amuiri, A. N., Zeltzer, E., Windon, C., Soleimani‐Meigooni, D. N., Tanner, J. A., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13453 · Cited by 89
Self-citationLatest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease
Milà-Alomà, M., Suárez-Calvet, M., & Molinuevo, J. L. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419888819 · Cited by 78
A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders
Manzano, S., Agüera, L., Aguilar, M., & Olazarán, J. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00614 · Cited by 87
Xie, S., Ji, Z., Suo, T., Li, B., & Zhang, X. (2021) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.338848 · Cited by 86
Descriptive Epidemiology of Neurodegenerative Diseases: What Are the Critical Questions?
Logroscino, G., Urso, D., & Savica, R. (2022) · Neuroepidemiology · doi:10.1159/000525639 · Cited by 85
Neuropathology of the Alzheimer's continuum: an update
Jellinger, K. A. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3050 · Cited by 84
RNA modulates physiological and neuropathological protein phase transitions
Mann, J. R., & Donnelly, C. J. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.023 · Cited by 85
Predictors of cognitive impairment in primary age-related tauopathy: an autopsy study
Iida, M. A., Farrell, K. W., Walker, J. M., Richardson, T. E., Marx, G. A., Bryce, C., Purohit, D. P., Ayalon, G., Beach, T. G., Bigio, E. H., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01233-3 · Cited by 83
Self-citationAssociation of APOE e2 genotype with Alzheimer’s and non-Alzheimer’s neurodegenerative pathologies
Goldberg, T. E., Huey, E. D., & Devanand, D. P. (2020) · Nature Communications · doi:10.1038/s41467-020-18198-x · Cited by 82
Boccalini, C., Ribaldi, F., Hristovska, I., Arnone, A., Peretti, D. E., Mu, L., Scheffler, M., Perani, D., Frisoni, G. B., & Garibotto, V. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13355 · Cited by 82
Gomes, L. A., Uytterhoeven, V., Lopez-Sanmartin, D., Tomé, S. O., Tousseyn, T., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Verstreken, P., & Thal, D. R. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02251-6 · Cited by 82
Lüningschrör, P., Werner, G., Stroobants, S., Kakuta, S., Dombert, B., Sinske, D., Wanner, R., Lüllmann-Rauch, R., Wefers, B., Wurst, W., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.060 · Cited by 78
Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD
Robinson, J. L., Yan, N., Caswell, C., Xie, S. X., Suh, E., Van Deerlin, V. M., Gibbons, G., Irwin, D. J., Grossman, M., Lee, E. B., et al. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz141 · Cited by 75
Self-citationQuadros, A. R. A. D. A., Li, Z., Wang, X., Ndayambaje, I. S., Aryal, S., Ramesh, N., Nolan, M., Jayakumar, R., Han, Y., Stillman, H., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02655-0 · Cited by 82
Self-citationAmidst an amygdala renaissance in Alzheimer’s disease
Stouffer, K. M., Grande, X., Düzel, E., Johansson, M., Creese, B., Witter, M. P., Miller, M. I., Wisse, L. E. M., & Berron, D. (2023) · Brain · doi:10.1093/brain/awad411 · Cited by 80
Fan, Y., Nirujogi, R. S., Garrido, A., Ruiz-Martínez, J., Bergareche-Yarza, A., Mondragón-Rezola, E., Vinagre-Aragón, A., Croitoru, I., Gorostidi Pagola, A., Paternain Markinez, L., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02325-z · Cited by 74
Neuropathologic burden and the degree of frailty in relation to global cognition and dementia
Wallace, L. M. K., Theou, O., Darvesh, S., Bennett, D. A., Buchman, A. S., Andrew, M. K., Kirkland, S. A., Fisk, J. D., & Rockwood, K. (2020) · Neurology · doi:10.1212/wnl.0000000000010944 · Cited by 79
Zamudio, F., Loon, A. R., Smeltzer, S., Benyamine, K., Navalpur Shanmugam, N. K., Stewart, N. J. F., Lee, D. C., Nash, K., & Selenica, M.-L. B. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01952-9 · Cited by 74
Peng, A. Y. T., Agrawal, I., Ho, W. Y., Yen, Y.-C., Pinter, A. J., Liu, J., Phua, Q. X. C., Koh, K. B., Chang, J.-C., Sanford, E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2007806117 · Cited by 75
Ramanan, V. K., Castillo, A. M., Knopman, D. S., Graff-Radford, J., Lowe, V. J., Petersen, R. C., Jack, C. R., Mielke, M. M., & Vemuri, P. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.13909 · Cited by 73
Self-citationLimbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration
Robinson, J. L., Porta, S., Garrett, F. G., Zhang, P., Xie, S. X., Suh, E. R., Deerlin, V. M. V., Abner, E. L., Jicha, G. A., Barber, J. M., et al. (2020) · Brain · doi:10.1093/brain/awaa219 · Cited by 78
Self-citationTDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains
Ayuso, V. E., Pickles, S. R., Todd, T. W., Yue, M., Jansen‐West, K. R., Song, Y., Bejarano, J. G., Rawlinson, B. D., Deture, M. A., Graff‐Radford, N. R., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00646-z · Cited by 78
Self-citationFrequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity
Moscoso, A., Heeman, F., Raghavan, S., Costoya‐Sánchez, A., van Essen, M., Mainta, I., Camacho, V., Fonseca, O. D. R., Silva‐Rodríguez, J., Perissinotti, A., et al. (2025) · JAMA · doi:10.1001/jama.2025.7817 · Cited by 78
Self-citationTDP-43 dysfunction results in R-loop accumulation and DNA replication defects
Wood, M. D., Quinet, A., Lin, Y., Davis, A. A., Pasero, P., Ayala, Y. M., & Vindigni, A. (2020) · Journal of Cell Science · doi:10.1242/jcs.244129 · Cited by 77
Josephs, K. A., Martin, P. R., Weigand, S. D., Tosakulwong, N., Buciuc, M., Murray, M. E., Petrucelli, L., Senjem, M. L., Spychalla, A. J., Knopman, D. S., et al. (2020) · Brain · doi:10.1093/brain/awaa299 · Cited by 78
Self-citationUltrastructural and biochemical classification of pathogenic tau, α-synuclein and TDP-43
Tarutani, A., Adachi, T., Akatsu, H., Hashizume, Y., Hasegawa, K., Saito, Y., Robinson, A., Mann, D. M. A., Yoshida, M., Murayama, S., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02426-3 · Cited by 78
Self-citationTDP-43 pathology is associated with increased tau burdens and seeding
Tomé, S. O., Tsaka, G., Ronisz, A., Ospitalieri, S., Gawor, K., Gomes, L. A., Otto, M., von Arnim, C. A. F., Van Damme, P., Van Den Bosch, L., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00653-0 · Cited by 66
François‐Moutal, L., Felemban, R. A., Scott, D. D., Sayegh, M., Miranda, V. G., Perez‐Miller, S., Khanna, R., Gokhale, V. M., Zarnescu, D. C., & Khanna, M. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00481 · Cited by 77
Bejanin, A., Murray, M. E., Martin, P. R., Botha, H., Tosakulwong, N., Schwarz, C. G., Senjem, M. L., Chételat, G., Kantarci, K., Jack, C. R., et al. (2019) · Brain · doi:10.1093/brain/awz277 · Cited by 77
Self-citationVascular pathology and pathogenesis of cognitive impairment and dementia in older adults
Agrawal, S., & Schneider, J. A. (2022) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2022.100148 · Cited by 76
Self-citationNag, S., & Schneider, J. A. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00846-7 · Cited by 76
Self-citationThe complex pathway between amyloid β and cognition: implications for therapy
Jagust, W. J., Teunissen, C. E., & DeCarli, C. S. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00128-x · Cited by 74
King, A., Bódi, I., & Troakes, C. (2020) · Brain Sciences · doi:10.3390/brainsci10080479 · Cited by 74
Kumar, S., Phaneuf, D., Cordeau, P., Boutej, H., Križ, J., & Julien, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00420-5 · Cited by 73
Grothe, M. J., Moscoso, A., Silva‐Rodríguez, J., Lange, C., Nho, K. T., Saykin, A. J., Nelson, P. T., Schöll, M., Buchert, R., Teipel, S. J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12763 · Cited by 75
Self-citationShade, L. M. P., Katsumata, Y., Abner, E. L., Aung, K. Z., Claas, S. A., Qiao, Q., Heberle, B. A., Brandon, J. A., Page, M. L., Hohman, T. J., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01939-9 · Cited by 72
“…amyloid-β plaques including diffuse plaques and Braak NFT staging 28–30 ), non-AD neurodegenerative pro-teinopathies (LATE-NC and Lewy bodies 12,31 ), cerebrovascular pathologies (CAA, gross infarcts, microinfarcts, circle of Willis atherosclerosis and arteriolosclerosis 30,32 ) and…”
InfluentialSelf-citationOrganismal Protein Homeostasis Mechanisms
Hoppe, T., & Cohen, E. (2020) · Genetics · doi:10.1534/genetics.120.301283 · Cited by 72
Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy
Walker, J. M., Richardson, T. E., Farrell, K. W., Iida, M. A., Foong, C., Shang, P., Attems, J., Ayalon, G., Beach, T. G., Bigio, E. H., et al. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa153 · Cited by 72
Self-citationContribution of TDP and hippocampal sclerosis to hippocampal volume loss in older-old persons
Yu, L., Boyle, P. A., Dawe, R. J., Bennett, D. A., Arfanakis, K., & Schneider, J. A. (2019) · Neurology · doi:10.1212/wnl.0000000000008679 · Cited by 73
Self-citationPathobiological Subtypes of Alzheimer Disease
Jellinger, K. A. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000508625 · Cited by 67
Aging, Diabetes, Obesity, and Cognitive Decline: A Population‐Based Study
Ganguli, M., Beer, J. C., Zmuda, J. M., Ryan, C. M., Sullivan, K., Chang, C. H., & Rao, R. H. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16321 · Cited by 71
Brini, S., Sohrabi, H. R., Hébert, J. J., Forrest, M. R. L., Laine, M., Hämäläinen, H., Karrasch, M., Peiffer, J. J., Martins, R. N., & Fairchild, T. J. (2020) · Neuropsychology Review · doi:10.1007/s11065-020-09426-8 · Cited by 71
Cognitive Impairment in Older Adults and Therapeutic Strategies
Montine, T. J., Bukhari, S. A., & White, L. R. (2020) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000031 · Cited by 71
Self-citationClinical Spectrum of Tauopathies
Olfati, N., Shoeibi, A., & Litvan, I. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.944806 · Cited by 71
When Alzheimer's is LATE : Why Does it Matter?
Nelson, P. T., Schneider, J. A., Jicha, G. A., Duong, M. T., & Wolk, D. A. (2023) · Annals of Neurology · doi:10.1002/ana.26711 · Cited by 71
Self-citationDickerson, B. C., Atri, A., Clevenger, C. K., Karlawish, J. H., Knopman, D. S., Lin, P., Norman, M., Onyike, C. U., Sano, M., Scanland, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14337 · Cited by 70
Squitti, R., Faller, P., Hureau, C., Granzotto, A., White, A. R., & Kepp, K. P. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201556 · Cited by 71
Morrone, C. D., Raghuraman, R., Hussaini, S. A., & Yu, W. H. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00617-4 · Cited by 69
Endocannabinoid system alterations in Alzheimer’s disease: A systematic review of human studies
Berry, A. J., Zubko, O., Reeves, S., & Howard, R. J. (2020) · Brain Research · doi:10.1016/j.brainres.2020.147135 · Cited by 69
Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia
Benussi, A., Alberici, A., Samra, K., Russell, L. L., Greaves, C. V., Bocchetta, M., Ducharme, S., Finger, E. C., Fumagalli, G., Galimberti, D., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12485 · Cited by 67
Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia
Kurnellas, M., Mitra, A., Schwabe, T., Paul, R. H., Arrant, A. E., Roberson, E. D., Ward, M. E., Yeh, F. L., Long, H., & Rosenthal, A. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04251-y · Cited by 67
Advances in Deep Neuropathological Phenotyping of Alzheimer Disease: Past, Present, and Future
Shakir, M., & Dugger, B. N. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab122 · Cited by 67
Josephs, K. A., Mackenzie, I., Frosch, M. P., Bigio, E. H., Neumann, M., Arai, T., Dugger, B. N., Ghetti, B., Grossman, M., Hasegawa, M., et al. (2019) · Brain · doi:10.1093/brain/awz224 · Cited by 66
Dugan, A. J., Nelson, P. T., Katsumata, Y., Shade, L. M. P., Boehme, K. L., Teylan, M., Cykowski, M. D., Mukherjee, S., Kauwe, J. S. K., Hohman, T. J., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01250-2 · Cited by 66
Self-citationFerri, R., Babiloni, C., Karami, V., Triggiani, A. I., Carducci, F., Noce, G., Lizio, R., Pascarelli, M. T., Soricelli, A., Amenta, F., et al. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2020.09.015 · Cited by 66
Cullen, N. C., Novak, P., Tosun, D., Kovacech, B., Hanes, J., Kontsekova, E., Fresser, M., Ropele, S., Feldman, H. H., Schmidt, R., et al. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2023.104923 · Cited by 54
Chen, P., Han, X., Shaw, T. I., Fu, Y., Sun, H., Niu, M., Wang, Z., Jiao, Y., Teubner, B. J. W., Eddins, D. M., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00290-0 · Cited by 64
Gittings, L. M., Alsop, E. B., Antone, J., Singer, M., Whitsett, T. G., Sattler, R., & Keuren‐Jensen, K. R. V. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02599-5 · Cited by 64
RNA-binding proteins in ALS and FTD: from pathogenic mechanisms to therapeutic insights
Rummens, J., & Cruz, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00851-y · Cited by 64
Neuroimaging in Dementia: More than Typical Alzheimer Disease
Haller, S., Jäger, H. R., Vernooij, M. W., & Barkhof, F. (2023) · Radiology · doi:10.1148/radiol.230173 · Cited by 63
Assessing Reactive Astrogliosis with 18 F-SMBT-1 Across the Alzheimer Disease Spectrum
Villemagne, V. L., Harada, R., Doré, V., Furumoto, S., Mulligan, R. S., Kudo, Y., Burnham, S. C., Krishnadas, N., Bourgeat, P., Xia, Y., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263255 · Cited by 63
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
Ossenkoppele, R., & Hansson, O. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12356 · Cited by 62
Uemura, M. T., Robinson, J. L., Cousins, K. A. Q., Tropea, T. F., Kargilis, D., McBride, J. D., Suh, E. R., Xie, S. X., Xu, Y., Porta, S., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02383-3 · Cited by 62
Self-citationPan-SHIP1/2 inhibitors promote microglia effector functions essential for CNS homeostasis
Pedicone, C., Fernandes, S., Dungan, O. M., Dormann, S. M., Viernes, D. R., Adhikari, A. A., Choi, L. B., De Jong, E. P., Chisholm, J. D., & Kerr, W. G. (2020) · Journal of Cell Science · doi:10.1242/jcs.238030 · Cited by 61
Sekiya, H., Tsuji, A., Hashimoto, Y., Takata, M., Koga, S., Nishida, K., Futamura, N., Kawamoto, M., Kohara, N., Dickson, D. W., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01440-6 · Cited by 61
Self-citationChang, K., Ling, J. P., Redding‐Ochoa, J., An, Y., Li, L., Dean, S. A., Blanchard, T. G., Pylyukh, T., Barrett, A., Irwin, K. E., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02653-2 · Cited by 61
Passive antiamyloid immunotherapy for Alzheimer's disease
Loureiro, J. C., Pais, M. V., Stella, F., Radanovic, M., Teixeira, A. L., Forlenza, O. V., & de Souza, L. C. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000587 · Cited by 56
O’Neill, K., Shaw, R., Bolger, I., Tam, O. H., Phatnani, H. P., & Hammell, M. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115402 · Cited by 61
TDP-43: From Alzheimer’s Disease to Limbic-Predominant Age-Related TDP-43 Encephalopathy
Huang, W., Zhou, Y., Tu, L., Ba, Z., Huang, J., Huang, N., & Luo, Y. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00026 · Cited by 60
Murray, M. E., Moloney, C. M., Kouri, N., Syrjanen, J. A., Matchett, B. J., Rothberg, D. M., Tranovich, J. F., Sirmans, T. N. H., Wiste, H. J., Boon, B. D. C., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00578-0 · Cited by 55
Self-citationNeurodegeneration cell per cell
Balusu, S., Praschberger, R., Lauwers, E., Strooper, B. D., & Verstreken, P. (2023) · Neuron · doi:10.1016/j.neuron.2023.01.016 · Cited by 59
Biofluid biomarkers in Alzheimer’s disease and other neurodegenerative dementias
Zetterberg, H., & Bendlin, B. B. (2026) · Nature · doi:10.1038/s41586-025-10018-w · Cited by 59
Iaccarino, L., La Joie, R., Edwards, L., Strom, A., Schonhaut, D. R., Ossenkoppele, R., Pham, J., Mellinger, T., Janabi, M., Baker, S. L., et al. (2021) · Cerebral Cortex · doi:10.1093/cercor/bhaa184 · Cited by 54
TDP-43 interacts with pathological τ protein in Alzheimer’s disease
Tomé, S. O., Gomes, L. A., Li, X., Vandenberghe, R. R., Tousseyn, T., & Thal, D. R. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02295-2 · Cited by 59
Fluid biomarkers in Alzheimer's disease
Simrén, J., Elmgren, A., Blennow, K., & Zetterberg, H. (2023) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2022.09.006 · Cited by 58
Metadata
- Authors
- Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., Coyle-Gilchrist, I. T. S., Chui, H. C., Fardo, D. W., Flanagan, M. E., Halliday, G., Hokkanen, S. R. K., Hunter, S., Jicha, G. A., Katsumata, Y., Kawas, C. H., Keene, C. D., Kovacs, G. G., Kukull, W. A., Levey, A. I., Makkinejad, N., Montine, T. J., Murayama, S., Murray, M. E., Nag, S., Rissman, R. A., Seeley, W. W., Sperling, R. A., White III, C. L., Yu, L., & Schneider, J. A.
- Affiliations
- University of Kentucky (US)
- Mayo Clinic in Florida (US)
- University of Pennsylvania (US)
- Mayo Clinic (US)
- Rush University Medical Center (US)
- Uppsala University (SE)
- Newcastle University (GB)
- University of Cambridge (GB)
- University of Southern California (US)
- University of Minnesota (US)
- The University of Sydney (AU)
- University of California, Irvine (US)
- University of Washington (US)
- Institute of Neurology Medical University of Vienna, Vienna, Austria
- Emory University (US)
- Illinois Institute of Technology (US)
- Stanford University (US)
- Tokyo Metropolitan Institute of Gerontology (JP)
- University of California San Diego (US)
- University of California, San Francisco (US)
- Harvard University (US)
- University of Texas Southwestern Medical Center, Dallas, TX, USA
- Corresponding author
- Nelson, Peter T
- ORCID
- Nelson, Peter T
- Dickson, Dennis W
- Trojanowski, John Q
- Jack, Clifford R
- Boyle, Patricia A
- Arfanakis, Konstantinos
- Rademakers, Rosa
- Alafuzoff, Irina
- Attems, Johannes
- Brayne, Carol
- Coyle-Gilchrist, Ian T S
- Chui, Helena C
- Fardo, David W
- Flanagan, Margaret E
- Halliday, Glenda
- Hokkanen, Suvi R K
- Hunter, Sally
- Jicha, Gregory A
- Katsumata, Yuriko
- Kawas, Claudia H
- Keene, C Dirk
- Kukull, Walter A
- Levey, Allan I
- Makkinejad, Nazanin
- Montine, Thomas J
- Murayama, Shigeo
- Murray, Melissa E
- Nag, Sukriti
- Rissman, Robert A
- Seeley, William W
- Sperling, Reisa A
- Yu, Lei
- Schneider, Julie A
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-04-30
- Volume
- 142
- Issue
- 6
- Pages
- 1503-1527
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6536849
- OpenAlex
- W2943828894
- Cited by
- 1,547
- References
- 276
- Citations by year
- 2026: 206 · 2025: 240 · 2024: 211 · 2023: 214 · 2022: 213 · 2021: 193 · 2020: 198 · 2019: 66
- FWCI
- 113.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UKnowledge (University of Kentucky) (submittedVersion, cc-by-nc)
- Apollo (University of Cambridge) (submittedVersion, cc-by-nc)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Apollo
- Funders
- NIA
- NACC
- NIH (U01 AG016976)
- National Health and Medical Research Council
- NHMRC (1132524, 1095127, 1037746)
- Senior Principal Research Fellowship (1079679)
- National Institutes of Health (P01 AG003949, R01 AG037491, P50 AG016574, R01 AG054449, P30 AG028303, P30 AG012300, P30 AG049638, P30 AG010124, P30 AG010161, P50 AG047366, P50 AG025688, P50 AG005131, R37 AG011378, R01 AG041851, R01 AG042210, R01 AG017917, R01 AG034374, UF1 AG053983, UF1 AG057707)
- NIHR (534906, NF-SI-0616–10090)
- National Institute for Health Research
- NHS
- Department of Health and Social Care
- Addenbrooke’s Charitable Trust
- Paul G. Allen Family Foundation and Alzheimer’s Research
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- limbic-predominant age-related TDP-43 encephalopathy, TDP-43 proteinopathy, hippocampal sclerosis, diagnostic criteria, neuropathological staging, amygdala, medial temporal lobe atrophy, genetic risk variants, gene regulatory networks, TMEM106B, ABCC9, apolipoprotein E, Alzheimer's disease, frontotemporal lobar degeneration
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Brain Diseases, Female, Humans, Male, Middle Aged, Retrospective Studies, Frontotemporal Lobar Degeneration, TDP-43 Proteinopathies, Frontotemporal Dementia, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.